How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes

Open access

How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes

Acute coronary syndromes are the leading cause of hospitalization and death. Results from recent studies suggest that apolipoprotein measurement and apoB:apoA-I are superior to traditional lipids in the estimation of coronary risk. We compared apolipoprotein concentrations and apoB:apoA-I with traditional lipid measures and atherogenic indices in patients diagnosed with acute coronary syndromes (ACS) within 6 hrs from the onset of chest pain. A study group consisted of 227 patients diagnosed with ACS (STEMI=60, NSTEMI=66 and UA=105). Clinically healthy volunteers (n=85) served as controls. Measurements of cardiac TnI, lipid profile, hsCRP, apolipoprotein A-I and apoB100 were performed and apoB:apoA-I, TC-HDL-C, LDL-C:HDL-C ratios were calculated. Patients had increased LDL-C (>3.0 mmol/L) and non-HDL-C (>3.4 mmol/L). Triglycerides were below the cut-off value, but patients had significantly higher TG concentrations and lower HDL-C compared to controls (p<0.001). Apo B and apoA-I concentration in patients remained within the accepted range. Atherogenic indices TC:HDL-C, LDL-C:HDL-C and apoB:apoA-I were significantly increased in patients. ApoB:apoA-I ratio in ACS males was within low risk whereas in females corresponded to medium risk. ApoB:apoA-I and LDL-C:HDL-C ratios were of good diagnostic utility for discrimination between patients and controls (AUC 0.71 and 0.79; respectively). ApoB:apoA-I and LDL-C:HDL-C were of very good diagnostic utility for discrimination between STEMI patients and controls (AUC 0.80 and 0.84). We could not show the superiority of apoB:apoA-I over LDL-C:HDL-C as the discrimination power of both was almost identical. Determination of apolipoproteins should not be recommended for routine clinical use, however, incorporating apoB and apoB:apoA-I into risk assessment could provide additional important information on cardiovascular risk.

Ogolnopolski Rejestr Ostrych Zespolow Wiencowych PL-ACS

Torres M, Moayedi S. Evaluation of the acutely dyspneic elderly patient. Clin Geriatr Med 2007; 23: 307-25.

Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009; 32: 9: 482-6.

Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259: 247-58.

Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Harnnon WH. International federation of clinical chemistry standardization project for measurements of apolipoprotein A-1 and B: IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994; 40: 586-92.

Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus. Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51: 1512-24.

Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small lowdensity lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-9.

Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. QJM 2006; 99: 277-87.

Eremić N, Đerić M. Evaluation of coronary risk score applications in 10-yaer coronary heart risk estimation. Journal of Medical Biochemistry 2009; 28: 145-151.

Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 507-14.

Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006; 259: 437-46.

Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116: 3090-100.

Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006; 259: 493-519.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.

Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108: 2312-16.

Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30: 2137-46.

Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 2009; 205: 284-9.

Iwahashi N, Kosuge M, Okuda J, Tsukahara K, Tahara Y, Hibi K, Ebina T, Sumita S, Ishikawa, Uchino K, Umemura S, Kimura K. Abstract 1364: Impact of the ApoB/A1-Ratio on the Prediction of the Elevation of Left Ventricular Filling Pressure After a First STEMI. Circulation 2009; 120: S489.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information

IMPACT FACTOR 2017: 1.378
5-year IMPACT FACTOR: 0.704

CiteScore 2017: 1.05

SCImago Journal Rank (SJR) 2017: 0.307
Source Normalized Impact per Paper (SNIP) 2017: 0.532


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 94 94 12
PDF Downloads 22 22 1